Pre-Procedural Use of Levosimendan in High-Risk ACS-PCI Patients with Reduced Left Ventricle Ejection Fraction—Short-Term Outcomes
Rattachement africain : pl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background/Objectives: Current evidence suggests that levosimendan may have a beneficial effect in the treatment of acute heart failure (AHF) or cardiogenic shock following primary percutaneous coronary intervention (PCI). However, there is a paucity of data on the use of levosimendan prior to PCI. Therefore, our pilot study aimed to assess the short-term prognosis of a new therapeutic protocol involving preprocedural infusion of levosimendan in patients with reduced left ventricular ejection fraction undergoing high-risk PCI for acute coronary syndrome (ACS). Methods: The study is a retrospective observational study, and the population includes all subjects who received levosimendan infusion prior to high-risk PCI for ACS. Subjects requiring urgent revascularization (cardiogenic shock, cardiac arrest) or with mechanical complications of ACS were excluded. Results: The study cohort consisted of 90 subjects, predominantly men (91.1%) with significantly reduced left ventricular function (28.7% (12)) and advanced coronary artery disease, mean SYNTAX Score 25.8 (19.3–33). During in-hospital follow-up, we observed 2 primary outcomes—death. The major adverse cardiac and cerebrovascular events (MACCE) rate was 7.8%. Two clinical adverse events that did not lead to discontinuation were observed during the in-hospital period. Both were related to hypotension. Conclusions: In short-term observation, novel therapeutic approach in the management of high-risk PCI in ACS patients—pre-procedural levosimendan—was a relatively safe approach. No significant adverse events were reported.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Pre-Procedural Use of Levosimendan in High-Risk ACS-PCI Patients with Reduced Left Ventricle Ejection Fraction—Short-Term Outcomes
- Date Crossref
- 17/04/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Wrocław University of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
Witelon State University of Applied Sciences in Legnica pays non établi dans la noticeUniversité ou école supérieure
-
AGH University of Krakow pays non établi dans la noticeUniversité ou école supérieure
-
Poznan University of Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
The Copper Health Centre (MCZ) Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Provincial Specialized Hospital Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Faculty of Medicine Department of Cardiology pays non établi dans la noticeUniversité ou école supérieure
Wrocław University of Science and Technology, Witelon State University of Applied Sciences in Legnica et AGH University of Krakow, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.